View in EDS

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.

Saved in:
Bibliographic Details
Title: Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
Authors: Margolis, David A., Gonzalez-Garcia, Juan, Stellbrink, Hans-Jürgen, Eron, Joseph J., Yazdanpanah, Yazdan, Podzamczer, Daniel, Lutz, Thomas, Angel, Jonathan B., Richmond, Gary J., Clotet, Bonaventura, Gutierrez, Felix, Sloan, Louis, Clair, Marty St, Murray, Miranda, Ford, Susan L., Mrus, Joseph, Patel, Parul, Crauwels, Herta, Griffith, Sandy K., Sutton, Kenneth C.
Source: Lancet. 9/23/2017, Vol. 390 Issue 10101, p1499-1510. 12p. 1 Diagram, 2 Charts, 3 Graphs.
Subjects: Rilpivirine, Antiretroviral agents, HIV infections, Abacavir-lamivudine (Drug), Nonsense suppression (Genetics), United States. Food & Drug Administration, Lamivudine, Pyridine, Anti-HIV agents, Reverse transcriptase inhibitors, Deoxyribonucleosides, Combination drug therapy, HIV, Intramuscular injections, World health, Viral load, Randomized controlled trials, Therapeutics
Abstract: Background: Cabotegravir and rilpivirine are antiretroviral drugs in development as long-acting injectable formulations. The LATTE-2 study evaluated long-acting cabotegravir plus rilpivirine for maintenance of HIV-1 viral suppression through 96 weeks.Methods: In this randomised, phase 2b, open-label study, treatment-naive adults infected with HIV-1 initially received oral cabotegravir 30 mg plus abacavir-lamivudine 600-300 mg once daily. The objective of this study was to select an intramuscular dosing regimen based on a comparison of the antiviral activity, tolerability, and safety of the two intramuscular dosing regimens relative to oral cabotegravir plus abacavir-lamivudine. After a 20-week induction period on oral cabotegravir plus abacavir-lamivudine, patients with viral suppression (plasma HIV-1 RNA <50 copies per mL) were randomly assigned (2:2:1) to intramuscular long-acting cabotegravir plus rilpivirine at 4-week intervals (long-acting cabotegravir 400 mg plus rilpivirine 600 mg; two 2 mL injections) or 8-week intervals (long-acting cabotegravir 600 mg plus rilpivirine 900 mg; two 3 mL injections) or continued oral cabotegravir plus abacavir-lamivudine. Randomisation was computer-generated with stratification by HIV-1 RNA (<50 copies per mL, yes or no) during the first 12 weeks of the induction period. The primary endpoints were the proportion of patients with viral suppression at week 32 (as defined by the US Food and Drug Administration snapshot algorithm), protocol-defined virological failures, and safety events through 96 weeks. All randomly assigned patients who received at least one dose of study drug during the maintenance period were included in the primary efficacy and safety analyses. The primary analysis used a Bayesian approach to evaluate the hypothesis that the proportion with viral suppression for each long-acting regimen is not worse than the oral regimen proportion by more than 10% (denoted comparable) according to a prespecified decision rule (ie, posterior probability for comparability >90%). Difference in proportions and associated 95% CIs were supportive to the primary analysis. The trial is registered at ClinicalTrials.gov, number NCT02120352.Findings: Among 309 enrolled patients, 286 were randomly assigned to the maintenance period (115 to each of the 4-week and 8-week groups and 56 to the oral treatment group). This study is currently ongoing. At 32 weeks following randomisation, both long-acting regimens met primary criteria for comparability in viral suppression relative to the oral comparator group. Viral suppression was maintained at 32 weeks in 51 (91%) of 56 patients in the oral treatment group, 108 (94%) of 115 patients in the 4-week group (difference 2·8% [95% CI -5·8 to 11·5] vs oral treatment), and 109 (95%) of 115 patients in the 8-week group (difference 3·7% [-4·8 to 12·2] vs oral treatment). At week 96, viral suppression was maintained in 47 (84%) of 56 patients receiving oral treatment, 100 (87%) of 115 patients in the 4-week group, and 108 (94%) of 115 patients in the 8-week group. Three patients (1%) experienced protocol-defined virological failure (two in the 8-week group; one in the oral treatment group). Injection-site reactions were mild (3648 [84%] of 4360 injections) or moderate (673 [15%] of 4360 injections) in intensity and rarely resulted in discontinuation (two [<1%] of 230 patients); injection-site pain was reported most frequently. Serious adverse events during maintenance were reported in 22 (10%) of 230 patients in the intramuscular groups (4-week and 8-week groups) and seven (13%) of 56 patients in the oral treatment group; none were drug related.Interpretation: The two-drug combination of all-injectable, long-acting cabotegravir plus rilpivirine every 4 weeks or every 8 weeks was as effective as daily three-drug oral therapy at maintaining HIV-1 viral suppression through 96 weeks and was well accepted and tolerated.Funding: ViiV Healthcare and Janssen R&D. [ABSTRACT FROM AUTHOR]
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 125412285
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Margolis%2C+David+A%2E%22&quot;&gt;Margolis, David A.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Gonzalez-Garcia%2C+Juan%22&quot;&gt;Gonzalez-Garcia, Juan&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Stellbrink%2C+Hans-J&#252;rgen%22&quot;&gt;Stellbrink, Hans-J&#252;rgen&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Eron%2C+Joseph+J%2E%22&quot;&gt;Eron, Joseph J.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Yazdanpanah%2C+Yazdan%22&quot;&gt;Yazdanpanah, Yazdan&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Podzamczer%2C+Daniel%22&quot;&gt;Podzamczer, Daniel&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Lutz%2C+Thomas%22&quot;&gt;Lutz, Thomas&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Angel%2C+Jonathan+B%2E%22&quot;&gt;Angel, Jonathan B.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Richmond%2C+Gary+J%2E%22&quot;&gt;Richmond, Gary J.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Clotet%2C+Bonaventura%22&quot;&gt;Clotet, Bonaventura&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Gutierrez%2C+Felix%22&quot;&gt;Gutierrez, Felix&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Sloan%2C+Louis%22&quot;&gt;Sloan, Louis&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Clair%2C+Marty+St%22&quot;&gt;Clair, Marty St&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Murray%2C+Miranda%22&quot;&gt;Murray, Miranda&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Ford%2C+Susan+L%2E%22&quot;&gt;Ford, Susan L.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Mrus%2C+Joseph%22&quot;&gt;Mrus, Joseph&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Patel%2C+Parul%22&quot;&gt;Patel, Parul&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Crauwels%2C+Herta%22&quot;&gt;Crauwels, Herta&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Griffith%2C+Sandy+K%2E%22&quot;&gt;Griffith, Sandy K.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Sutton%2C+Kenneth+C%2E%22&quot;&gt;Sutton, Kenneth C.&lt;/searchLink&gt;
– Name: TitleSource
  Label: Source
  Group: Src
  Data: &lt;searchLink fieldCode=&quot;JN&quot; term=&quot;%22Lancet%22&quot;&gt;Lancet&lt;/searchLink&gt;. 9/23/2017, Vol. 390 Issue 10101, p1499-1510. 12p. 1 Diagram, 2 Charts, 3 Graphs.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Rilpivirine%22&quot;&gt;Rilpivirine&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Antiretroviral+agents%22&quot;&gt;Antiretroviral agents&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22HIV+infections%22&quot;&gt;HIV infections&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Abacavir-lamivudine+%28Drug%29%22&quot;&gt;Abacavir-lamivudine (Drug)&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Nonsense+suppression+%28Genetics%29%22&quot;&gt;Nonsense suppression (Genetics)&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22United+States%2E+Food+%26+Drug+Administration%22&quot;&gt;United States. Food &amp; Drug Administration&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Lamivudine%22&quot;&gt;Lamivudine&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Pyridine%22&quot;&gt;Pyridine&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Anti-HIV+agents%22&quot;&gt;Anti-HIV agents&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Reverse+transcriptase+inhibitors%22&quot;&gt;Reverse transcriptase inhibitors&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Deoxyribonucleosides%22&quot;&gt;Deoxyribonucleosides&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Combination+drug+therapy%22&quot;&gt;Combination drug therapy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22HIV%22&quot;&gt;HIV&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Intramuscular+injections%22&quot;&gt;Intramuscular injections&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22World+health%22&quot;&gt;World health&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Viral+load%22&quot;&gt;Viral load&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Randomized+controlled+trials%22&quot;&gt;Randomized controlled trials&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Therapeutics%22&quot;&gt;Therapeutics&lt;/searchLink&gt;
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: &lt;bold&gt;Background: &lt;/bold&gt;Cabotegravir and rilpivirine are antiretroviral drugs in development as long-acting injectable formulations. The LATTE-2 study evaluated long-acting cabotegravir plus rilpivirine for maintenance of HIV-1 viral suppression through 96 weeks.&lt;bold&gt;Methods: &lt;/bold&gt;In this randomised, phase 2b, open-label study, treatment-naive adults infected with HIV-1 initially received oral cabotegravir 30 mg plus abacavir-lamivudine 600-300 mg once daily. The objective of this study was to select an intramuscular dosing regimen based on a comparison of the antiviral activity, tolerability, and safety of the two intramuscular dosing regimens relative to oral cabotegravir plus abacavir-lamivudine. After a 20-week induction period on oral cabotegravir plus abacavir-lamivudine, patients with viral suppression (plasma HIV-1 RNA &lt;50 copies per mL) were randomly assigned (2:2:1) to intramuscular long-acting cabotegravir plus rilpivirine at 4-week intervals (long-acting cabotegravir 400 mg plus rilpivirine 600 mg; two 2 mL injections) or 8-week intervals (long-acting cabotegravir 600 mg plus rilpivirine 900 mg; two 3 mL injections) or continued oral cabotegravir plus abacavir-lamivudine. Randomisation was computer-generated with stratification by HIV-1 RNA (&lt;50 copies per mL, yes or no) during the first 12 weeks of the induction period. The primary endpoints were the proportion of patients with viral suppression at week 32 (as defined by the US Food and Drug Administration snapshot algorithm), protocol-defined virological failures, and safety events through 96 weeks. All randomly assigned patients who received at least one dose of study drug during the maintenance period were included in the primary efficacy and safety analyses. The primary analysis used a Bayesian approach to evaluate the hypothesis that the proportion with viral suppression for each long-acting regimen is not worse than the oral regimen proportion by more than 10% (denoted comparable) according to a prespecified decision rule (ie, posterior probability for comparability &gt;90%). Difference in proportions and associated 95% CIs were supportive to the primary analysis. The trial is registered at ClinicalTrials.gov, number NCT02120352.&lt;bold&gt;Findings: &lt;/bold&gt;Among 309 enrolled patients, 286 were randomly assigned to the maintenance period (115 to each of the 4-week and 8-week groups and 56 to the oral treatment group). This study is currently ongoing. At 32 weeks following randomisation, both long-acting regimens met primary criteria for comparability in viral suppression relative to the oral comparator group. Viral suppression was maintained at 32 weeks in 51 (91%) of 56 patients in the oral treatment group, 108 (94%) of 115 patients in the 4-week group (difference 2&#183;8% [95% CI -5&#183;8 to 11&#183;5] vs oral treatment), and 109 (95%) of 115 patients in the 8-week group (difference 3&#183;7% [-4&#183;8 to 12&#183;2] vs oral treatment). At week 96, viral suppression was maintained in 47 (84%) of 56 patients receiving oral treatment, 100 (87%) of 115 patients in the 4-week group, and 108 (94%) of 115 patients in the 8-week group. Three patients (1%) experienced protocol-defined virological failure (two in the 8-week group; one in the oral treatment group). Injection-site reactions were mild (3648 [84%] of 4360 injections) or moderate (673 [15%] of 4360 injections) in intensity and rarely resulted in discontinuation (two [&lt;1%] of 230 patients); injection-site pain was reported most frequently. Serious adverse events during maintenance were reported in 22 (10%) of 230 patients in the intramuscular groups (4-week and 8-week groups) and seven (13%) of 56 patients in the oral treatment group; none were drug related.&lt;bold&gt;Interpretation: &lt;/bold&gt;The two-drug combination of all-injectable, long-acting cabotegravir plus rilpivirine every 4 weeks or every 8 weeks was as effective as daily three-drug oral therapy at maintaining HIV-1 viral suppression through 96 weeks and was well accepted and tolerated.&lt;bold&gt;Funding: &lt;/bold&gt;ViiV Healthcare and Janssen R&amp;D. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: &lt;i&gt;Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder&#39;s express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.&lt;/i&gt; (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=125412285
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S0140-6736(17)31917-7
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 12
        StartPage: 1499
    Subjects:
      – SubjectFull: Rilpivirine
        Type: general
      – SubjectFull: Antiretroviral agents
        Type: general
      – SubjectFull: HIV infections
        Type: general
      – SubjectFull: Abacavir-lamivudine (Drug)
        Type: general
      – SubjectFull: Nonsense suppression (Genetics)
        Type: general
      – SubjectFull: United States. Food & Drug Administration
        Type: general
      – SubjectFull: Lamivudine
        Type: general
      – SubjectFull: Pyridine
        Type: general
      – SubjectFull: Anti-HIV agents
        Type: general
      – SubjectFull: Reverse transcriptase inhibitors
        Type: general
      – SubjectFull: Deoxyribonucleosides
        Type: general
      – SubjectFull: Combination drug therapy
        Type: general
      – SubjectFull: HIV
        Type: general
      – SubjectFull: Intramuscular injections
        Type: general
      – SubjectFull: World health
        Type: general
      – SubjectFull: Viral load
        Type: general
      – SubjectFull: Randomized controlled trials
        Type: general
      – SubjectFull: Therapeutics
        Type: general
    Titles:
      – TitleFull: Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Margolis, David A.
      – PersonEntity:
          Name:
            NameFull: Gonzalez-Garcia, Juan
      – PersonEntity:
          Name:
            NameFull: Stellbrink, Hans-Jürgen
      – PersonEntity:
          Name:
            NameFull: Eron, Joseph J.
      – PersonEntity:
          Name:
            NameFull: Yazdanpanah, Yazdan
      – PersonEntity:
          Name:
            NameFull: Podzamczer, Daniel
      – PersonEntity:
          Name:
            NameFull: Lutz, Thomas
      – PersonEntity:
          Name:
            NameFull: Angel, Jonathan B.
      – PersonEntity:
          Name:
            NameFull: Richmond, Gary J.
      – PersonEntity:
          Name:
            NameFull: Clotet, Bonaventura
      – PersonEntity:
          Name:
            NameFull: Gutierrez, Felix
      – PersonEntity:
          Name:
            NameFull: Sloan, Louis
      – PersonEntity:
          Name:
            NameFull: Clair, Marty St
      – PersonEntity:
          Name:
            NameFull: Murray, Miranda
      – PersonEntity:
          Name:
            NameFull: Ford, Susan L.
      – PersonEntity:
          Name:
            NameFull: Mrus, Joseph
      – PersonEntity:
          Name:
            NameFull: Patel, Parul
      – PersonEntity:
          Name:
            NameFull: Crauwels, Herta
      – PersonEntity:
          Name:
            NameFull: Griffith, Sandy K.
      – PersonEntity:
          Name:
            NameFull: Sutton, Kenneth C.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 23
              M: 09
              Text: 9/23/2017
              Type: published
              Y: 2017
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 390
            – Type: issue
              Value: 10101
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1